ReviewClinical reviews in allergy & immunology2021
Challenge of Nail Psoriasis: An Update Review.
Review in Clinical reviews in allergy & immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- A comprehensive overview of psoriatic research over the past 20 years: machine learning-based bibliometric analysis.Frontiers in immunology · 2023Pooled it
- A Comprehensive Evaluation of the Efficacy of Intense Pulsed Light and Neodymium-doped Yttrium Aluminum Garnet Laser Treatments in Nail Psoriasis.Dermatology practical & conceptual · 2026Article
- Severe Nail Psoriasis and Early Psoriatic Arthritis: Illustrative Cases Confirming That Severity of Disease Is Not Solely Dependent on the Extent of Body Surface Area.The Journal of clinical and aesthetic dermatology · 2026Article
- NasalJournal of inflammation research · 2026Article
- Imbalance of TCA-related miRNA-mRNA networks involving IDH2, SDHA, SDHC, and SUCLG1 drives psoriasis development.Frontiers in physiology · 2026Article
- Treatment of Isolated Nail Psoriasis with JAK Inhibitor Tofacitinib: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Psychiatric Comorbidities in Patients with Psoriasis: A 10-Year Retrospective Epidemiological Study from a Tertiary University Center in Northeastern Romania.Medicina (Kaunas, Lithuania) · 2025Article
- Balancing efficacy and hepatotoxicity: a comprehensive review of oral medications in psoriasis management.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Article
- Epidemiological Profile of Psoriasis and Linked Comorbidities in Chinese Population at Shenzhen: A Cross-Sectional Study.Health science reports · 2025Article
- Clinical and Ultrasonographic Assessment of Nail Psoriasis: A Comprehensive Study.Dermatology practical & conceptual · 2025Article
- [Nail psoriasis-painful and yet undertreated : From pathogenesis to therapy].Dermatologie (Heidelberg, Germany) · 2025Article
- Predictors of Quality of Life in Psoriasis Patients: Insights from a Cross-Sectional Study.Psoriasis (Auckland, N.Z.) · 2025Article
- Prevalence of tobacco smoking and its association with disease severity and psoriatic arthritis among patients with nail psoriasis in China: a cross-sectional study.Frontiers in medicine · 2025Article
- Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends.Recent advances in inflammation & allergy drug discovery · 2025Review
- Skin and Nail Predictors of Psoriatic Arthritis Development: A Holistic Overview Integrating Epidemiological and Physiopathological Data.Journal of clinical medicine · 2024Review
- Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- [Treatment of psoriasis vulgaris : Therapy strategies for optimal patient-centered care].Dermatologie (Heidelberg, Germany) · 2024Review
- Article
- Single-Cell Sequencing and Machine Learning Integration to Identify Candidate Biomarkers in Psoriasis:Journal of inflammation research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nail psoriasis is a refractory disease that affects 50-79% skin psoriasis patients and up to 80% of patients with psoriatic arthritis (PsA). The pathogenesis of nail psoriasis is still not fully illuminated, although some peculiar inflammatory cytokines and chemokines seems to be the same as described in psoriatic skin lesions. Psoriatic nail involving matrix can cause pitting, leukonychia, red spots in lunula, and nail plate crumbling, while nail bed involvement can result in onycholysis, oil-drop discoloration, nail bed hyperkeratosis, and splinter hemorrhages. The common assessment methods of evaluating nail psoriasis includes Nail Psoriasis Severity Index (NAPSI), Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA), Nail Psoriasis Quality of life 10 (NPQ10), and so on. Treatment of nail psoriasis should be individualized according to the number of involving nail, the affected site of nail and presence of skin and/or joint involvement. Generally, topical therapies are used for mild nail psoriasis, while biologic agents such as etanercept are considered for severe nail disease and refractory nail psoriasis. Even though the current literature has shown some support for the pathogenesis, clinical presentation, or therapies of nail psoriasis, systemic review of this multifaceted disease is still rare to date. We elaborate recent developments in nail psoriasis epidemiology, pathogenesis, anatomy, clinical manifestation, diagnosis, differential diagnosis, and therapies to raise better awareness of the complexity of nail psoriasis and the need for early diagnosis or intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.